Following recent data from the ADRIATIC study, the Oncology Brothers and Eric Singhi, MD, discuss the role of prophylactic cranial irradiation (PCI) in patients with small cell lung cancer.
Vobramitamab Duocarmazine Does Not Achieve Responses in R/R ES-SCLC
After failing to record any objective responses in 9 patients with relapsed/refractory ES-SCLC, the phase 2 trial was terminated early.
Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting
Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.
Durvalumab Combo Enhances OS vs Chemo Alone in Treatment-Naive ES-SCLC
Rates of grade 3 or 4 AEs with durvalumab were similar across subgroups, with serious AEs more frequent in patients 70 years or older with ES-SCLC.
Considering Dosing and AE Management Strategies With Tarlatamab in SCLC
Experts from Washington University in St. Louis discuss prior data and strategies for mitigating toxicities like CRS associated with tarlatamab in SCLC.
Lung Oncologists Take to Social Media to Highlight Impactful WCLC Abstracts
Leveraging #WCLC25, lung oncologists spoke about the presentations they’re most looking forward to at the upcoming conference.
Atezolizumab Plus Chemo Is Safe, Efficacious in Broader ES-SCLC Population
The median overall survival with atezolizumab plus carboplatin and etoposide was 10.6 months in patients with extensive-stage small cell lung cancer.